MAPT and Alzheimer disease: Likewise, maraviroc, a CCR5 antagonist, significantly reduces the HIV-induced AD-like brain pathologies, including Aβ deposition and tau hyperphosphorylation, which may result from the increased transendothelial Aβ transport via LRP1 pathways (Bhargavan et al., 2021).